All Deals
April 2, 2025 - Deals
Isomorphic Labs Secures $600 Million Funding Led By Thrive Capital With Partners Eli Lilly And Novartis
Isomorphic Labs, the AI drug discovery platform spun out of DeepMind in 2021, has raised $600 million in its first external funding round led by Thrive Capital, with participation from GV and Alphabet. Founded by DeepMind co-founder Demis Hassabis, the company leverages AI models like AlphaFold to accelerate drug design. The funding will support further development and hiring of top research talent. Isomorphic Labs has secured partnerships with Eli Lilly and Novartis, potentially generating up to $3 billion in milestone payments.
INVESTORS: Thrive Capital, GV & Alphabet
AMOUNT: $600,000,000
HQ: #London #UnitedKingdom
#VentureCapital #IsomorphicLabs #ThriveCapital #GV #Alphabet #DemisHassabis #TradedVC
More Deals
View All
Colossal Biosciences In Talks For Funding Round Targeting $23 Billion ValuationColossal Biosciences, the de-extinction biotech startup known for its efforts to recreate the woolly mammoth and other extinct species, is reportedly in talks to raise new funding at a valuation of roughly $23 billion–$24 billion, according to Axios. The potential raise would mark a significant jump for the five-year-old company, with investors valuing not only its genetic-engineering programs but also its broader genomics, reproductive technology, conservation, and intellectual property platform. Colossal has begun generating revenue through conservation technology sales and technology spinouts, including Astromech, an AI-driven predictive modeling company, and Form Bio, a computational biology platform, expanding its value beyond de-extinction efforts.
FOUNDERS: Ben Lamm & George Church
TARGET VALUATION: $23,000,000,000
HQ: Dallas, Texas
#VentureCapital #ColossalBiosciences #BenLamm #GeorgeChurch #TradedVC